Clinical trial

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

NCT03411161

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-01-04

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2018-01-04Date precision: day

Registry last updated2021-05-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Breast Cancerunresolved

Metastatic Triple Negative Breast Cancerunresolved

Interventions

Combination therapy (S81694 + paclitaxel) phase IDRUG

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Combination therapy (S81694 + paclitaxel) phase IIDRUG

Sponsors & collaborators

Institut de Recherches Internationales Servierlead sponsor

ADIR, a Servier Group companycollaborator

Mapped research locations

BrusselsBelgium1 LeuvenBelgium1 OsakaJapan1 RotterdamNetherlands1 Saint-HerblainFrance1 ChibaJapan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03411161 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.